Obreztchikova M, et al. (2006) Distinct signaling functions for Shc isoforms in the heart. J Biol Chem 281, 20197-204 16699171

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

S473-p - Akt1 (rat) ▲

Modsite: RPHFPQFsYSASGTA SwissProt Entrez-Gene Orthologous residues Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p Characterization Methods used to characterize site in vivo:  electrophoretic mobility shift, phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  fibroblast-heart Cellular systems studied:  primary cells Species studied:  rat Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes isoproterenol no change compared to control thrombin increase AG1478 thrombin inhibit treatment-induced increase EGF increase AG1478 EGF inhibit treatment-induced increase

T203-p - ERK1 (rat) ▲

Modsite: HDHTGFLtEyVAtRW SwissProt Entrez-Gene Orthologous residues ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p Characterization Methods used to characterize site in vivo:  electrophoretic mobility shift, phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  fibroblast-heart Cellular systems studied:  primary cells Species studied:  rat Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes thrombin increase AG1478 thrombin inhibit treatment-induced increase PP1 thrombin inhibit treatment-induced increase U0126 thrombin inhibit treatment-induced increase phorbol_ester increase PTX thrombin no effect upon treatment-induced increase AG1478 phorbol_ester inhibit treatment-induced increase PP1 phorbol_ester no effect upon treatment-induced increase U0126 phorbol_ester inhibit treatment-induced increase EGF increase AG1478 EGF inhibit treatment-induced increase PP1 EGF no effect upon treatment-induced increase U0126 EGF inhibit treatment-induced increase isoproterenol increase AG1478 isoproterenol inhibit treatment-induced increase PTX isoproterenol inhibit treatment-induced increase angiotensin_2 increase H2O2 increase Pasteurella_multocida_toxin increase

Y205-p - ERK1 (rat) ▲

Modsite: HTGFLtEyVAtRWYR SwissProt Entrez-Gene Orthologous residues ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p Characterization Methods used to characterize site in vivo:  electrophoretic mobility shift, phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  fibroblast-heart Cellular systems studied:  primary cells Species studied:  rat Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes thrombin increase AG1478 thrombin inhibit treatment-induced increase PP1 thrombin inhibit treatment-induced increase U0126 thrombin inhibit treatment-induced increase phorbol_ester increase PTX thrombin no effect upon treatment-induced increase AG1478 phorbol_ester inhibit treatment-induced increase PP1 phorbol_ester no effect upon treatment-induced increase U0126 phorbol_ester inhibit treatment-induced increase EGF increase AG1478 EGF inhibit treatment-induced increase PP1 EGF no effect upon treatment-induced increase U0126 EGF inhibit treatment-induced increase isoproterenol increase AG1478 isoproterenol inhibit treatment-induced increase PTX isoproterenol inhibit treatment-induced increase angiotensin_2 increase H2O2 increase Pasteurella_multocida_toxin increase

T183-p - ERK2 (rat) ▲

Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene Orthologous residues ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p Characterization Methods used to characterize site in vivo:  electrophoretic mobility shift, phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  fibroblast-heart Cellular systems studied:  primary cells Species studied:  rat Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes thrombin increase AG1478 thrombin inhibit treatment-induced increase PP1 thrombin inhibit treatment-induced increase U0126 thrombin inhibit treatment-induced increase phorbol_ester increase PTX thrombin no effect upon treatment-induced increase AG1478 phorbol_ester inhibit treatment-induced increase PP1 phorbol_ester no effect upon treatment-induced increase U0126 phorbol_ester inhibit treatment-induced increase EGF increase AG1478 EGF inhibit treatment-induced increase PP1 EGF no effect upon treatment-induced increase U0126 EGF inhibit treatment-induced increase isoproterenol increase AG1478 isoproterenol inhibit treatment-induced increase PTX isoproterenol inhibit treatment-induced increase angiotensin_2 increase H2O2 increase Pasteurella_multocida_toxin increase

Y185-p - ERK2 (rat) ▲

Modsite: HtGFLtEyVAtRWYR SwissProt Entrez-Gene Orthologous residues ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p Characterization Methods used to characterize site in vivo:  electrophoretic mobility shift, phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  fibroblast-heart Cellular systems studied:  primary cells Species studied:  rat Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes thrombin increase AG1478 thrombin inhibit treatment-induced increase PP1 thrombin inhibit treatment-induced increase U0126 thrombin inhibit treatment-induced increase phorbol_ester increase PTX thrombin no effect upon treatment-induced increase AG1478 phorbol_ester inhibit treatment-induced increase PP1 phorbol_ester no effect upon treatment-induced increase U0126 phorbol_ester inhibit treatment-induced increase EGF increase AG1478 EGF inhibit treatment-induced increase PP1 EGF no effect upon treatment-induced increase U0126 EGF inhibit treatment-induced increase isoproterenol increase AG1478 isoproterenol inhibit treatment-induced increase PTX isoproterenol inhibit treatment-induced increase angiotensin_2 increase H2O2 increase Pasteurella_multocida_toxin increase

S36-p - SHC1 (rat) ▲

Modsite: TPPEELPsPSASSLG SwissProt Entrez-Gene Orthologous residues SHC1 (human): S36‑p, SHC1 iso2 (human): ‑, SHC1 iso3 (human): ‑, SHC1 iso6 (human): S36‑p, SHC1 iso7 (human): ‑, SHC1 (mouse): S36‑p, SHC1 iso2 (mouse): ‑, SHC1 iso3 (mouse): ‑, SHC1 (rat): S36‑p, SHC1 iso2 (rat): ‑ Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes thrombin increase AG1478 thrombin inhibit treatment-induced increase PP1 thrombin inhibit treatment-induced increase U0126 thrombin inhibit treatment-induced increase phorbol_ester increase GF109203X phorbol_ester inhibit treatment-induced increase AG1478 phorbol_ester inhibit treatment-induced increase PP1 phorbol_ester no effect upon treatment-induced increase U0126 phorbol_ester inhibit treatment-induced increase H2O2 increase EGF increase AG1478 EGF inhibit treatment-induced increase PP1 EGF inhibit treatment-induced increase U0126 EGF inhibit treatment-induced increase isoproterenol no change compared to control norepinephrine increase Pasteurella_multocida_toxin increase U0126 Pasteurella_multocida_toxin inhibit treatment-induced increase GF109203X Pasteurella_multocida_toxin inhibit treatment-induced increase

Y349-p - SHC1 (rat) ▲

Modsite: EEPPDHQyyNDFPGK SwissProt Entrez-Gene Orthologous residues SHC1 (human): Y349‑p, SHC1 iso2 (human): Y239‑p, SHC1 iso3 (human): Y194‑p, SHC1 iso6 (human): Y349‑p, SHC1 iso7 (human): Y239‑p, SHC1 (mouse): Y349‑p, SHC1 iso2 (mouse): Y239‑p, SHC1 iso3 (mouse): Y194‑p, SHC1 (rat): Y349‑p, SHC1 iso2 (rat): Y239‑p Characterization Methods used to characterize site in vivo:  electrophoretic mobility shift, phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  fibroblast-heart Cellular systems studied:  primary cells Species studied:  rat Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes isoproterenol no change compared to control H2O2 increase thrombin increase AG1478 thrombin inhibit treatment-induced increase PP1 thrombin inhibit treatment-induced increase phorbol_ester increase AG1478 phorbol_ester inhibit treatment-induced increase PP1 phorbol_ester inhibit treatment-induced increase EGF increase AG1478 EGF inhibit treatment-induced increase PP1 EGF no effect upon treatment-induced increase

Y350-p - SHC1 (rat) ▲

Modsite: EPPDHQyyNDFPGKE SwissProt Entrez-Gene Orthologous residues SHC1 (human): Y350‑p, SHC1 iso2 (human): Y240‑p, SHC1 iso3 (human): Y195‑p, SHC1 iso6 (human): Y350‑p, SHC1 iso7 (human): Y240‑p, SHC1 (mouse): Y350‑p, SHC1 iso2 (mouse): Y240‑p, SHC1 iso3 (mouse): Y195‑p, SHC1 (rat): Y350‑p, SHC1 iso2 (rat): Y240‑p Characterization Methods used to characterize site in vivo:  electrophoretic mobility shift, phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  fibroblast-heart Cellular systems studied:  primary cells Species studied:  rat Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes isoproterenol no change compared to control H2O2 increase thrombin increase AG1478 thrombin inhibit treatment-induced increase PP1 thrombin inhibit treatment-induced increase phorbol_ester increase AG1478 phorbol_ester inhibit treatment-induced increase PP1 phorbol_ester inhibit treatment-induced increase EGF increase AG1478 EGF inhibit treatment-induced increase PP1 EGF no effect upon treatment-induced increase

Y423-p - SHC1 (rat) ▲

Modsite: ELFDDPSyVNIQNLD SwissProt Entrez-Gene Orthologous residues SHC1 (human): Y427‑p, SHC1 iso2 (human): Y317‑p, SHC1 iso3 (human): Y272‑p, SHC1 iso6 (human): Y428‑p, SHC1 iso7 (human): Y318‑p, SHC1 (mouse): Y423‑p, SHC1 iso2 (mouse): Y313‑p, SHC1 iso3 (mouse): Y268‑p, SHC1 (rat): Y423‑p, SHC1 iso2 (rat): Y313‑p Characterization Methods used to characterize site in vivo:  electrophoretic mobility shift, phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  fibroblast-heart Cellular systems studied:  primary cells Species studied:  rat Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes thrombin increase AG1478 thrombin inhibit treatment-induced increase PP1 thrombin inhibit treatment-induced increase phorbol_ester increase AG1478 phorbol_ester inhibit treatment-induced increase PP1 phorbol_ester inhibit treatment-induced increase EGF increase AG1478 EGF inhibit treatment-induced increase PP1 EGF no effect upon treatment-induced increase

Y239-p - SHC1 iso2 (rat) ▲

Modsite: EELPDHQyyNDFPGK SwissProt Entrez-Gene Orthologous residues SHC1 (human): Y349‑p, SHC1 iso2 (human): Y239‑p, SHC1 iso3 (human): Y194‑p, SHC1 iso6 (human): Y349‑p, SHC1 iso7 (human): Y239‑p, SHC1 (mouse): Y349‑p, SHC1 iso2 (mouse): Y239‑p, SHC1 iso3 (mouse): Y194‑p, SHC1 (rat): Y349‑p, SHC1 iso2 (rat): Y239‑p Characterization Methods used to characterize site in vivo:  electrophoretic mobility shift, phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  fibroblast-heart Cellular systems studied:  primary cells Species studied:  rat Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes thrombin increase AG1478 thrombin inhibit treatment-induced increase PP1 thrombin inhibit treatment-induced increase phorbol_ester increase AG1478 phorbol_ester inhibit treatment-induced increase PP1 phorbol_ester inhibit treatment-induced increase EGF increase AG1478 EGF inhibit treatment-induced increase PP1 EGF no effect upon treatment-induced increase isoproterenol no change compared to control H2O2 increase

Y240-p - SHC1 iso2 (rat) ▲

Modsite: ELPDHQyyNDFPGKE SwissProt Entrez-Gene Orthologous residues SHC1 (human): Y350‑p, SHC1 iso2 (human): Y240‑p, SHC1 iso3 (human): Y195‑p, SHC1 iso6 (human): Y350‑p, SHC1 iso7 (human): Y240‑p, SHC1 (mouse): Y350‑p, SHC1 iso2 (mouse): Y240‑p, SHC1 iso3 (mouse): Y195‑p, SHC1 (rat): Y350‑p, SHC1 iso2 (rat): Y240‑p Characterization Methods used to characterize site in vivo:  electrophoretic mobility shift, phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  fibroblast-heart Cellular systems studied:  primary cells Species studied:  rat Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes thrombin increase AG1478 thrombin inhibit treatment-induced increase PP1 thrombin inhibit treatment-induced increase phorbol_ester increase AG1478 phorbol_ester inhibit treatment-induced increase PP1 phorbol_ester inhibit treatment-induced increase EGF increase AG1478 EGF inhibit treatment-induced increase PP1 EGF no effect upon treatment-induced increase isoproterenol no change compared to control H2O2 increase

Y313-p - SHC1 iso2 (rat) ▲

Modsite: ELFDDPSyVNIQNLD SwissProt Entrez-Gene Orthologous residues SHC1 (human): Y427‑p, SHC1 iso2 (human): Y317‑p, SHC1 iso3 (human): Y272‑p, SHC1 iso6 (human): Y428‑p, SHC1 iso7 (human): Y318‑p, SHC1 (mouse): Y423‑p, SHC1 iso2 (mouse): Y313‑p, SHC1 iso3 (mouse): Y268‑p, SHC1 (rat): Y423‑p, SHC1 iso2 (rat): Y313‑p Characterization Methods used to characterize site in vivo:  electrophoretic mobility shift, phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  fibroblast-heart Cellular systems studied:  primary cells Species studied:  rat Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes thrombin increase AG1478 thrombin inhibit treatment-induced increase PP1 thrombin inhibit treatment-induced increase phorbol_ester increase AG1478 phorbol_ester inhibit treatment-induced increase PP1 phorbol_ester inhibit treatment-induced increase EGF increase AG1478 EGF inhibit treatment-induced increase PP1 EGF no effect upon treatment-induced increase